Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788656 · ClinicalTrials.gov registry record · Phase 4
Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02788656 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 4 participants.
The verdict
NCT02788656, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
This pilot study will assess the impact of sacubitril/valsartan (trade name Entresto) on the elevated pulmonary artery pressures in patients with heart failure with reduced ejection fraction, measured using a previously implanted hemodynamic monitoring device (CardioMEMS).
Interventions
- DRUG sacubitril/valsartan
- DEVICE Implantable Hemodynamic Monitor
- DRUG Angiotensin-Converting Enzyme Inhibitor
- DRUG Angiotensin II Type 1 Receptor Blocker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-11-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02788656
The ClinicalTrials.gov registry entry for NCT02788656 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which sacubitril/valsartan is the first listed.
NCT02788656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02788656 about?
NCT02788656 is a clinical study titled "Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)". This pilot study will assess the impact of sacubitril/valsartan (trade name Entresto) on the elevated pulmonary artery pressures in patients with heart failure with reduced ejection fraction, measured using a previously implanted hemodynamic monitoring device (CardioMEMS).
What is the current status of trial NCT02788656?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2016-09. Estimated completion is 2018-11-09.
What interventions are being tested in trial NCT02788656?
The interventions under investigation include: sacubitril/valsartan (DRUG), Implantable Hemodynamic Monitor (DEVICE), Angiotensin-Converting Enzyme Inhibitor (DRUG), Angiotensin II Type 1 Receptor Blocker (DRUG).
Who is sponsoring clinical trial NCT02788656?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.